Zacks9d agoneutral
ImmunityBio to Report Q1 Earnings: What's in the Cards?IBRX's Q1 outlook rides on Anktiva's surging uptake, with preliminary revenues showing triple-digit growth ahead of its earnings report later this month.
News
High-signal headlines only — macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
309last 24h
1802last 7d
320🟢 bullish (7d)
187🔴 bearish (7d)
129publishers